Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Microscopic Hematuria an Unreliable Indicator of Bladder Cancer

By LabMedica International staff writers
Posted on 04 Feb 2013
A study found that microscopic hematuria does not necessarily mean cancer, and has led to a new model to predict renal and bladder cancer risk better.

Blood found in urine that cannot be seen by the naked eye does not necessarily indicate the presence of cancer, according to a Kaiser Permanente Southern California (Gardena, CA, USA) study published in the January 11, 2013, online version of the journal Mayo Clinic Proceedings. Tests routinely done on patients with this condition could be avoided and has led to the creation of a screening tool to better diagnose certain types of cancers.

The study examined the electronic health records of more than 4,000 patients with microscopic hematuria who were members of Kaiser Permanente health plans in Southern California, Northern California, and the Pacific Northwest between January 2009 and August 2011. The study found that an extremely small proportion of patients with microscopic hematuria were subsequently discovered to have cancer. Among the 4,414 patients who were evaluated for the condition, only 2.3% were diagnosed with bladder cancer and only 0.2% had a pathologically confirmed diagnosis of renal cancer.

Pathology reports were reviewed for all patients with cancer diagnoses. A total of 50 cancers (44 bladder and 6 renal) were confirmed in the test cohort and 61 cancers (56 bladder and 5 renal) in the validation cohort. In the test cohort, 5 of 55 neoplasms were benign on the final pathology report, and 1 patient with a 1.7-cm, enhancing renal lesion elected close observation and was counted as having stage T1 cancer. In the validation cohort, 56 of 59 bladder cancers were confirmed as were 5 of 7 renal cancers (2 renal lesions were benign hemorrhagic renal cysts). The overall cancer detection rate was 1.9% in the test cohort (50 of 2630 patients) and 3.4% for the validation cohort (61 of 1784 patients).

Overall, 100 bladder cancers were diagnosed among 4414 patients evaluated (2.3%), and only 11 renal cancers were pathologically confirmed (0.2%).

It is probable that patients with microscopic hematuria, especially those under 50 years of age and with no history of gross hematuria, may not benefit from further evaluation, and therefore could avoid routine tests that contain unnecessary risks such as radiation exposure from CT scans and invasive endoscopy.

“This study provides scientific data that confirms what others have suspected—that microscopic hematuria is an unreliable indicator of renal or bladder cancer,” said study lead author Ronald K. Loo, MD, and regional chief of urology for the Southern California Permanente Medical Group. “This suggests that a large number of follow-up examinations of patients with asymptomatic microscopic hematuria, which often includes radiologic and invasive procedures, could be safely avoided.”

Related Links:
Kaiser Permanente Southern California



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.